CIBAR2

Across TCGA pan-cancer cohorts, CIBAR2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CIBAR2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CIBAR2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CIBAR2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and GBM are the cancer types where CIBAR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.470	0.210	.014	25	view →
LUAD	DFS	Tertile	III,IV	0.464	1.000	.040	3	view →
GBM	OS	Tertile	All	0.244	0.668	.034	2	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.337	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CIBAR2–PDAC (DFS)

Open the PDAC breakdown →